Latest H5N1 clinical trials Stories
Global partnership enabled testing in Mali, West Africa, where malaria threat is high.
An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found.
VIENNA, Austria, January 13 /PRNewswire/ -- - By Starting the Phase II Study for deltaFLU, AVIR Green Hills AG has Accomplished yet Another Milestone in the Development of this Novel Influenza Vaccine.
BEIJING, Dec. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.
The FDA this week approved Fluzone High-Dose, an inactivated influenza virus vaccine for people ages 65 years and older to prevent disease caused by influenza virus subtypes A and B.
One dose of vaccine may be effective to protect infants and children and reduce transmission of the H1N1 virus, according to a study in JAMA, published online today because of its public health implications.
LYON, France and SWIFTWATER, Pa., Dec. 15 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced today that it is expanding its phase II clinical study of a vaccine against Clostridium difficile infection (CDI) into the United States.
The European Medicines Agency announced that young children who are receiving GlaxoSmithKline's H1N1 vaccine may contract a fever after the second injection.
ROCKVILLE, Md., Dec. 2 /PRNewswire-FirstCall/ -- Novavax, Inc.
BEIJING, Dec. 1 /PRNewswire-Asia/ -- Sinovac Biotech Ltd.